Metagenomi reports Q2 EPS (54c), consensus (61c)

Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and marketable securities, which it anticipates will support operations into 2027. Based on current information, the company plans to submit an investigational new drug and clinical trial application for its MGX-001 Hemophilia A program in 2026. “Entering the second half of the year, we continue to advance our MGX-001 wholly-owned program for hemophilia A towards pre-IND and ex-U.S. regulatory meetings in 2025, and our collaboration with Ionis in cardiometabolic indications towards nomination of development candidates in 2025,” said Brian Thomas, PhD, CEO and founder of Metagenomi (MGX). “Our strong balance sheet and continued focus on operational efficiency are enabling investment in both our pipeline and AI-driven metagenomics platform.”